Author | Diaz-Lagares, Angel | |
Author | Crujeiras, Ana B | |
Author | Lopez-Serra, Paula | |
Author | Soler, Marta | |
Author | Setien, Fernando | |
Author | Goyal, Ashish | |
Author | Sandoval, Juan | |
Author | Hashimoto, Yutaka | |
Author | Cardús, Anna Martinez | |
Author | Gomez, Antonio | |
Author | Heyn, Holger | |
Author | Moutinho, Catia | |
Author | Espada, Jesús | |
Author | Vidal, August | |
Author | Paúles, Maria | |
Author | Galán, Maica | |
Author | Sala, Núria | |
Author | Akiyama, Yoshimitsu | |
Author | Martínez-Iniesta, María | |
Author | Vallve, Maria de Lourdes Farre | |
Author | Villanueva, Alberto | |
Author | Gross, Matthias | |
Author | Diederichs, Sven | |
Author | Guil, Sonia | |
Author | Esteller, Manel | |
Access date | 2017-03-24T13:57:19Z | |
Available date | 2017-03-24T13:57:19Z | |
Document date | 2016 | |
Citation | DIAZ-LAGARES, A. et al. Epigenetic inactivation of the p53-induced long noncoding RNA TP53 target 1 in human cancer. Proceedings of the National Academy of Sciences, E7535–E7544, 2016. | pt_BR |
ISSN | 1091-6490 | pt_BR |
URI | https://www.arca.fiocruz.br/handle/icict/18161 | |
Description | Maria de Lourdes Farré Vallve - Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Laboratório de Patologia Experimental. Salvador, BA, Brasil. aCancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, 08908 Barcelona, Catalonia, Spain; bCentro de Investigación Biomédica en Red (CIBER) Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto Salud Carlos III, 28029 Madrid, Spain; cEndocrine Division, Complejo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain; dDivision of RNA Biology and Cancer (B150), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; eInstitute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany; fExperimental Dermatology and Skin Biology Group, Ramón y Cajal Institute for Biomedical Research (IRYCIS), Ramón y Cajal University Hospital, 28034 Madrid, Spain; gBionanotechnology Laboratory, Bernardo O’Higgins University, Santiago 8370854, Chile; hPathology Department, Hospital Universitari de Bellvitge, IDIBELL, L’Hospitalet de Llobregat, 08907 Barcelona, Catalonia, Spain; iDepartment of Medical Oncology, Catalan Institute of Oncology (ICO), IDIBELL, L’Hospitalet de Llobregat, 08908 Barcelona, Catalonia, Spain; jUnit of Nutrition and Cancer, Cancer Epidemiology Research Program, ICO, IDIBELL, 08908 Barcelona, Catalonia, Spain; kDepartment of Molecular Oncology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 113-8510 Tokyo, Japan; lProgram Against Cancer Therapeutic Resistance (ProCURE), ICO, IDIBELL, L’Hospitalet del Llobregat, 08908 Barcelona, Catalonia, Spain; mLaboratory of Experimental Pathology (LAPEX), Gonçalo Moniz Research Center, Oswaldo Cruz Foundation (CPQGM/ FIOCRUZ) and National Institute of Science and Technology of Tropical Diseases (INCT/DT), 40296710 Salvador, Bahia, Brazil; nDivision of Cancer Research, Department of Thoracic Surgery, Medical Center–University of Freiburg, 79106 Freiburg, Germany; oFaculty of Medicine, University of Freiburg, 79106 Freiburg, Germany; pGerman Cancer Consortium (DKTK), 79106 Freiburg, Germany; qDepartament de Ciències Fisiològiques II, Escola de Medicina, Universitat de Barcelona, 08907 Barcelona, Catalonia, Spain; and rInstitució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Catalonia, Spain | pt_BR |
Language | eng | pt_BR |
Publisher | National Academy of Sciences | pt_BR |
Rights | open access | pt_BR |
Subject in Portuguese | Metilação do DNA | pt_BR |
Subject in Portuguese | RNA | pt_BR |
Subject in Portuguese | Epigenética | pt_BR |
Subject in Portuguese | Cancer | pt_BR |
Title | Epigenetic inactivation of the p53-induced long noncoding RNA TP53 target 1 in human cancer | pt_BR |
Type | Article | pt_BR |
DOI | 10.1073/pnas.1608585113 | |
Abstract | Long noncoding RNAs (lncRNAs) are important regulators of cellular homeostasis. However, their contribution to the cancer phenotype still needs to be established. Herein, we have identified a p53-induced lncRNA, TP53TG1, that undergoes cancer-specific promoter hypermethylation-associated silencing. In vitro and in vivo assays identify a tumor-suppressor activity for TP53TG1 and a role in the p53 response to DNA damage. Importantly, we show that TP53TG1 binds to the multifaceted DNA/RNA binding protein YBX1 to prevent its nuclear localization and thus the YBX1-mediated activation of oncogenes. TP53TG1 epigenetic inactivation in cancer cells releases the transcriptional repression of YBX1-targeted growth-promoting genes and creates a chemoresistant tumor. TP53TG1 hypermethylation in primary tumors is shown to be associated with poor outcome. The epigenetic loss of TP53TG1 therefore represents an altered event in an lncRNA that is linked to classical tumoral pathways, such as p53 signaling, but is also connected to regulatory networks of the cancer cell. | pt_BR |
Affilliation | Bellvitge Biomedical Research Institute (IDIBELL). L’Hospitalet de Llobregat. Cancer Epigenetics and Biology Program (PEBC). Barcelona, Catalonia, Spain | pt_BR |
Affilliation | Bellvitge Biomedical Research Institute (IDIBELL). L’Hospitalet de Llobregat. Cancer Epigenetics and Biology Program (PEBC). Barcelona, Catalonia, Spain / Instituto Salud Carlos III. Centro de Investigación Biomédica en Red (CIBER) Fisiopatología de la Obesidad y Nutrición (CIBERobn). Madrid, Spain / Complejo Hospitalario Universitario de Santiago. Endocrine Division. Santiago de Compostela, Spain | pt_BR |
Affilliation | Bellvitge Biomedical Research Institute (IDIBELL). L’Hospitalet de Llobregat. Cancer Epigenetics and Biology Program (PEBC). Barcelona, Catalonia, Spain. Múltipla - ver em Notas | pt_BR |
Subject | DNA methylation | pt_BR |
Subject | Long noncoding RNA | pt_BR |
Subject | Epigenetics | pt_BR |
Subject | Cancer | pt_BR |